FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159254757> ?p ?o ?g. }

• W2159254757 endingPage "1218" @default.
• W2159254757 startingPage "1207" @default.
• W2159254757 abstract "To review the use of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (CML) and provide recommendations for managing adverse events (AEs) to maximise patient benefit.Treatment of CML has been revolutionised with the advent of tyrosine kinase inhibitors (TKIs) that target the breakpoint cluster region-Abelson (BCR-ABL) kinase. Imatinib is the only first-line TKI currently available for the treatment of CML; however, intolerance and resistance remain significant clinical challenges. The approved second-line treatment options for CML are dasatinib, nilotinib or escalated-dose imatinib.Review article.Searches of PubMed, ASCO and ASH electronic databases for relevant search terms were performed between July 2008-January 2009.Dasatinib has no cross-intolerance with imatinib, and the most frequent AEs (cytopenias and pleural and pericardial effusions) can generally be managed by dose interruption and reduction. Nilotinib has a high degree of haematologic cross-intolerance with first-line imatinib. As might be expected, high-dose imatinib has the potential for more severe AEs than standard-dose imatinib.There are known safety issues inherent to each TKI and close monitoring by nursing staff is necessary to identify and effectively manage AEs.All three TKIs have demonstrated potential for fluid retention and cardiotoxicity. Nurses should be aware of how these AEs manifest and intervene appropriately. The safety profiles of these TKIs clearly differs and it is important to consider factors such as comorbidities when making treatment decisions." @default.
• W2159254757 created "2016-06-24" @default.
• W2159254757 creator A5076396878 @default.
• W2159254757 date "2010-04-08" @default.
• W2159254757 modified "2023-10-16" @default.
• W2159254757 title "Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia" @default.
• W2159254757 cites W1970962784 @default.
• W2159254757 cites W1974565168 @default.
• W2159254757 cites W1990020715 @default.
• W2159254757 cites W1990406235 @default.
• W2159254757 cites W1998593414 @default.
• W2159254757 cites W2003973314 @default.
• W2159254757 cites W2004492241 @default.
• W2159254757 cites W2006917576 @default.
• W2159254757 cites W2020092689 @default.
• W2159254757 cites W2023117511 @default.
• W2159254757 cites W2028728760 @default.
• W2159254757 cites W2028959752 @default.
• W2159254757 cites W2040396943 @default.
• W2159254757 cites W2057718276 @default.
• W2159254757 cites W2070683532 @default.
• W2159254757 cites W2079446921 @default.
• W2159254757 cites W2080125373 @default.
• W2159254757 cites W2097946794 @default.
• W2159254757 cites W2107268345 @default.
• W2159254757 cites W2116153687 @default.
• W2159254757 cites W2119010176 @default.
• W2159254757 cites W2124196948 @default.
• W2159254757 cites W2274981692 @default.
• W2159254757 cites W2281742031 @default.
• W2159254757 cites W2312804644 @default.
• W2159254757 cites W2558733660 @default.
• W2159254757 cites W2565606062 @default.
• W2159254757 cites W2576284040 @default.
• W2159254757 cites W2587803351 @default.
• W2159254757 cites W2612051898 @default.
• W2159254757 doi "https://doi.org/10.1111/j.1365-2702.2009.03167.x" @default.
• W2159254757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20345830" @default.
• W2159254757 hasPublicationYear "2010" @default.
• W2159254757 type Work @default.
• W2159254757 sameAs 2159254757 @default.
• W2159254757 citedByCount "7" @default.
• W2159254757 countsByYear W21592547572012 @default.
• W2159254757 countsByYear W21592547572013 @default.
• W2159254757 countsByYear W21592547572014 @default.
• W2159254757 countsByYear W21592547572022 @default.
• W2159254757 crossrefType "journal-article" @default.
• W2159254757 hasAuthorship W2159254757A5076396878 @default.
• W2159254757 hasConcept C121608353 @default.
• W2159254757 hasConcept C126322002 @default.
• W2159254757 hasConcept C143998085 @default.
• W2159254757 hasConcept C170493617 @default.
• W2159254757 hasConcept C197934379 @default.
• W2159254757 hasConcept C2776694085 @default.
• W2159254757 hasConcept C2777413986 @default.
• W2159254757 hasConcept C2777583451 @default.
• W2159254757 hasConcept C2778208673 @default.
• W2159254757 hasConcept C2778233292 @default.
• W2159254757 hasConcept C2778729363 @default.
• W2159254757 hasConcept C2778820342 @default.
• W2159254757 hasConcept C2779536868 @default.
• W2159254757 hasConcept C3019892230 @default.
• W2159254757 hasConcept C42362537 @default.
• W2159254757 hasConcept C71924100 @default.
• W2159254757 hasConcept C98274493 @default.
• W2159254757 hasConceptScore W2159254757C121608353 @default.
• W2159254757 hasConceptScore W2159254757C126322002 @default.
• W2159254757 hasConceptScore W2159254757C143998085 @default.
• W2159254757 hasConceptScore W2159254757C170493617 @default.
• W2159254757 hasConceptScore W2159254757C197934379 @default.
• W2159254757 hasConceptScore W2159254757C2776694085 @default.
• W2159254757 hasConceptScore W2159254757C2777413986 @default.
• W2159254757 hasConceptScore W2159254757C2777583451 @default.
• W2159254757 hasConceptScore W2159254757C2778208673 @default.
• W2159254757 hasConceptScore W2159254757C2778233292 @default.
• W2159254757 hasConceptScore W2159254757C2778729363 @default.
• W2159254757 hasConceptScore W2159254757C2778820342 @default.
• W2159254757 hasConceptScore W2159254757C2779536868 @default.
• W2159254757 hasConceptScore W2159254757C3019892230 @default.
• W2159254757 hasConceptScore W2159254757C42362537 @default.
• W2159254757 hasConceptScore W2159254757C71924100 @default.
• W2159254757 hasConceptScore W2159254757C98274493 @default.
• W2159254757 hasIssue "9-10" @default.
• W2159254757 hasLocation W21592547571 @default.
• W2159254757 hasLocation W21592547572 @default.
• W2159254757 hasOpenAccess W2159254757 @default.
• W2159254757 hasPrimaryLocation W21592547571 @default.
• W2159254757 hasRelatedWork W1554937972 @default.
• W2159254757 hasRelatedWork W2112875208 @default.
• W2159254757 hasRelatedWork W2116887545 @default.
• W2159254757 hasRelatedWork W2145835848 @default.
• W2159254757 hasRelatedWork W2184746615 @default.
• W2159254757 hasRelatedWork W2413121165 @default.
• W2159254757 hasRelatedWork W2488200262 @default.
• W2159254757 hasRelatedWork W2587803351 @default.
• W2159254757 hasRelatedWork W4230849756 @default.
• W2159254757 hasRelatedWork W4366584823 @default.
• W2159254757 hasVolume "19" @default.

• next